REPORT OF THE TWENTIETH WHOPES

WORKING GROUP MEETING

/WHO/HQ, GENEVA /20–24 MARCH 2017

Review of:

INTERCEPTOR G2 LN
DAWAPLUS 3.0 LN
DAWAPLUS 4.0 LN
SUMILARV 2 MR
CHLORFENAPYR 240 SC



REPORT OF THE TWENTIETH WHOPES WORKING GROUP MEETING

WHO/HQ, GENEVA 20-24 MARCH 2017

REVIEW OF:

INTERCEPTOR G2 LN
DAWAPLUS 3.0 LN
DAWAPLUS 4.0 LN
SUMILARV 2 MR
CHLORFENAPYR 240 SC



CONTROL OF NEGLECTED TROPICAL DISEASES WHO PESTICIDE EVALUATION SCHEME

WHO/HTM/NTD/WHOPES/2017.04

© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Report of the twentieth WHOPES working group meeting, WHO/HQ, Geneva, 20–24 March 2017: review of Interceptor G2LN, DawaPlus 3.0 LN, DawaPlus 4.0 LN, SumiLarv 2 MR, Chlorfenapyr 240 SC. Geneva: World Health Organization; 2017 (WHO/HTM/NTD/WHOPES/2017.04). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int /bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

The recommendations of the World Health Organization Pesticide Evaluation Scheme (WHOPES) are intended to facilitate the registration and use of the evaluated products by the Member States of the World Health Organization. A recommendation or interim recommendation concerning a specific product means that the World Health Organization has

evaluated that product in laboratory and field trials and that the product was found to meet the criteria and requirements of the World Health Organization.

For long-lasting insecticidal mosquito nets (LNs), the World Health Organization may – pending the completion of long-term studies that may be required to fully evaluate such LNs and subject to certain conditions being met – issue an interim recommendation for the use of such LNs for prevention and control of malaria.

A recommendation or interim recommendation does not imply any approval by the World Health Organization of the product in question (which is the sole prerogative of national authorities).

Such a recommendation or interim recommendation does not, furthermore, constitute any assurance by the World Health Organization that the manufacture, distribution, sale and/or use of the product in question is in accordance with the national laws and regulations of any country, including, but not limited to, patent law.

The recommendations and interim recommendations included in this publication may not be used by manufacturers, suppliers or any other parties for commercial or promotional purposes. Manufacturers are, however, permitted to discreetly mention the outcome of the WHOPES evaluation in non-commercial material which is addressed to national public health professionals and/or pesticide registration authorities only (that is, through a statement that the product in question was found to have been manufactured in accordance with the applicable specification recommended by the World Health Organization).

A recommendation or interim recommendation does not constitute an endorsement, or warranty of the fitness, by the World Health Organization of any product for a particular purpose, nor does such a recommendation or interim recommendation constitute the expression of any opinion whatsoever about the product's suitability for the control of any given pest, or for use in any particular geographical area.

Printed in France.

CONTENTS

		Page
1. INTRODU	UCTION	1
2. REVIEW	OF INTERCEPTOR G2 LN	4
2.1	Safety assessment	4
2.2	Efficacy – background and supporting documents	
2.3	Efficacy – WHOPES supervised trials	
	2.3.1 Laboratory study	
	2.3.2 Experimental hut studies	
2.4	Conclusions and recommendations	29
3. REVIEW	OF DAWAPLUS 3.0 LN AND DAWAPLUS 4.0 LN	47
3.1	Safety assessment	47
3.2	Efficacy – WHOPES supervised trials	
	3.2.1 Laboratory study	
	3.2.2 Experimental hut studies	
3.3	Conclusions and recommendations	65
4. REVIEW	OF SUMILARV 2 MR	78
4.1	Safety assessment	
4.2	Efficacy – background and supporting documents	
4.3	Efficacy – WHOPES supervised trials	
	4.3.1 Small-scale trials	
	4.3.2 Large-scale field trials	84
4.4	Conclusions and recommendations	88
5. RE-EVAL	LUATION OF CHLORFENAPYR 240 SC	96
5.1	Efficacy – dataset submitted by the manufacturer	97
5.2	Small-scale field trials	
5.3	Conclusions and recommendations	104
6. GENERA	AL DISCUSSION	114
ANNEX 1. L	LIST OF PARTICIPANTS	116
ANNEY 2	REFERENCES	112
	\LI LI\LI\ULU	1 10

1. INTRODUCTION

The 20th meeting of the WHOPES Working Group, an advisory group to the World Health Organization Pesticide Evaluation Scheme (WHOPES), was held at WHO headquarters in Geneva, Switzerland from 20 to 24 March 2017.

The Working Group reviewed three long-lasting insecticidal net products for the prevention and control of malaria: Interceptor G2 LN of BASF, Germany; DawaPlus 3.0 LN and DawaPlus 4.0 LN of Tana Netting, United Arab Emirates; one mosquito larvicide: SumiLarv 2 MR of Sumitomo Chemical Co. Ltd., Japan; and re-evaluated Chlorfenapyr 240 SC of BASF, Germany. The Working Group made recommendations on the use and further evaluation of each of these products.

The meeting was opened by Dr Dirk Engels, Director, WHO Department of Control of Neglected Tropical Diseases (NTD). He said that WHO is undertaking reforms in evaluation of innovative tools, improving quality in the system, and ensuring standardized vector control evaluation and timely development of normative guidance. Evaluation of vector control products has moved to the WHO prequalification team effective January 2017.

As part of the NTD Vector Ecology and Management (VEM) unit, WHOPES will continue to play a normative role in the evaluation of vector control products, which involves developing standard operating procedures as well as efficacy testing guidelines and their necessary revisions periodically. WHOPES will continue collaboration with the Food and Agriculture Organization of the United Nations (FAO) in pesticide management activities to reduce risks to humans and the environment by providing guidelines and capacity strengthening support. Capacity building in vector control is our priority. In 2016, the VEM team started strengthening capacity of five sites in Asia leading to Good Laboratory Practice certification, and it is planned to add five more sites in 2017 including from Latin America.

Vector control is critical to the control and elimination of NTDs and malaria, and effective tools and strategies are paramount to these efforts. The Seventieth World Health Assembly (Geneva, 22–31 May 2017) will consider adopting a Global Vector Control Response; and NTD has focused on control of rapidly expanding arboviral diseases, in particular Zika virus disease, dengue and chikungunya.

Dr Engels noted that this is the last WHOPES Working Group meeting after which the prequalification team will assume the assessment function for products within the established categories. He thanked all the WHOPES Working Group members and hoped that the VEM unit will continue collaboration in normative activities.

¹ Refers to long-lasting insecticidal nets (LNs) as a pesticide formulation.

Dr Rajpal Yadav, Scientist in charge of WHOPES, briefed the Working Group on the objectives of the meeting, summarized the interests declared by the invited experts and explained the working procedures of the meeting. He too thanked all the WHOPES Working Group members for their excellent contributions to and technical support for the work of WHOPES.

Professor Dr Marc Coosemans, Institute for Tropical Medicine, Belgium was appointed as Chairperson and Dr John Gimnig, Centers for Disease Control and Prevention, USA as Rapporteur.

Nine invited experts and six staff representing the WHO Secretariat attended the meeting (see Annex 1. List of participants). The Working Group met in both plenary and break-out sessions, in which the reports of the WHOPES supervised trials and additional background reports submitted by the manufacturers including the relevant published literature and unpublished reports were reviewed and discussed (see Annex 2. References).

Declarations of interest

All the invited experts completed a *Declaration of interests for WHO experts* within the past four years before the meeting for assessment by the WHO Secretariat. The following interests were declared:

Dr Nicole Achee's university has received mosquito repellent products free of charge from SC Johnson & Son, USA for use in a large-scale intervention trial funded by the Bill & Melinda Gates Foundation, USA.

Dr Rajendra Bhatt's institute has received prescribed fees from BASF India Ltd., India; Bayer CropScience, India; and Vestergaard Frandsen, India to meet the costs of product evaluation.

Dr Fabrice Chandre's institute has received prescribed standard fees from Bayer CropScience, Germany to meet the costs of evaluation of their pasticide products

预览已结束, 完整报告键

https://www.yunbaogao.cn/report/index/